PSY

This fund is designed to mirror a systematically constructed index. This index evaluates the performance of companies engaged in specific, legally authorized activities, always in adherence to national laws. These activities encompass the fields of medical psychedelics, therapeutic cannabis, cannabis-derived pharmaceuticals, cannabidiol (CBD) derivatives, and ketamine. To achieve its financial goals, the fund utilizes a full replication approach, meaning it directly invests in all the constituent securities of the underlying index, striving to maintain their proportional weightings. It functions as a non-diversified investment product.